Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7377255 | 0.81 | LMNA (0.44) | KMT2ALMNASMN1; SMN2PDE4BHTT | |
| SCHEMBL1442168 | 0.80 | MAPT (0.43) | KMT2ALMNASMN1; SMN2PDE4BHTT | |
| SCHEMBL9360855 | 0.80 | SMN1; SMN2 (0.43) | KMT2ALMNASMN1; SMN2PDE4BHTT | |
| SCHEMBL22400987 | 0.80 | LMNA (0.43) | KMT2ALMNASMN1; SMN2PDE4BHTT | |
| SCHEMBL5410660 | 0.77 | LRRK2 (0.41) | KMT2ALMNASMN1; SMN2PDE4BHTT | |
| SCHEMBL25234983 | 0.76 | KDM4E (0.40) | KMT2ALMNASMN1; SMN2PDE4BHTT | |
| SCHEMBL15633418 | 0.76 | PTGS2 (0.43) | KMT2ALMNASMN1; SMN2PDE4BHTT | |
| SCHEMBL25243394 | 0.76 | KDR (0.44) | KMT2ALMNASMN1; SMN2HTTNPSR1 | |
| SCHEMBL31726565 | 0.76 | KDR (0.44) | KMT2ALMNASMN1; SMN2HTTNPSR1 | |
| SCHEMBL6880043 | 0.71 | HTT (0.51) | KMT2ALMNASMN1; SMN2PDE4BHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105130908-B | The preparation method and its synthetic intermediate of the cyano methyl pyrimidine of 4,6 dialkoxy 2 | 组合化学工业株式会社 | 2018-03-27 | — | — | CN | disclosed |
| CN-106959345-A | A kind of full Isotopic Internal Standard mass spectrum quantitative approach of neurotransmitter metabolite | 上海谱领生物科技有限公司 | 2017-07-18 | — | — | CN | disclosed |
| CN-105026376-A | Process for the preparation of bispyribac-sodium and intermediates thereof | GHARDA CHEMICALS LTD | 2015-11-04 | — | — | CN | disclosed |
| CN-102093298-A | Pyrimidine ring-containing benzoyl(thio)carbamide compounds with insecticidal activity | UNIV HUAZHONG NORMAL | 2011-06-15 | — | — | CN | disclosed |
| CN-101489544-A | Method for treating hematological disorders | HEMAQUEST PHARMACEUTICALS INC (US) | 2009-07-22 | — | — | CN | disclosed |
| CN-101339187-A | Methylsulfonyl miazines isotope labelling reagent, synthesis method and uses thereof | SHANGHAI INST ORGANIC CHEM (CN) | 2009-01-07 | — | — | CN | disclosed |
| CN-100418955-C | Novel Benzo-fused heterocycles | ACTELION PHARMOUEUTICALS LTD (CH) | 2008-09-17 | — | — | CN | disclosed |
| CN-1285581-C | Process for the preparation of 4, 6-dimethoxy-2- (methylsulfonyl) -1, 3-pyrimidine | SYNGENTA PARITCIPATIONS AG (CH) | 2006-11-22 | — | — | CN | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| CN-1151137-C | Preparation method of thiobarbituric acid derivative | �����ɷ� | 2004-05-26 | — | — | CN | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| CN-1339029-A | Method of producing thiobarbituric acid derivatives | SINGENTA PARTICIPATION AG (CH) | 2002-03-06 | — | — | CN | disclosed |
| WO-2002008207-A1 | PROCESS FOR THE PREPARATION OF 4,6-DIMETHOXY-2-(METHYLSULFONYL)-1,3-PYRIMIDINE | SYNGENTA PARTICIPATIONS AG (CH) | 2002-01-31 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| US-5627138-A | HERBICIDES | SANDOZ LTD. (CH) | 1997-05-06 | — | — | US | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
| US-5167693-A | Pre- and postemergence | BAYER AKTIENGESELLSCHAFT (DE) | 1992-12-01 | — | — | US | disclosed |
| EP-0435104-A2 | Salicylic acid derivatives, process for their preparation and their use as herbicide and bioregulators | BASF Aktiengesellschaft (DE) | 1991-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | KMT2A 2702/4885LMNA 380/4885SMN1; SMN2 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.